David Norwood
Chaiman
Bussiness
Oxford Pharmaceuticals
United States of America
Biography
David Norwood is a founding shareholder in Oxford Pharmascience. David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses and a shareholder in the Company. Previously, he was Chief Executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (recently acquired by Investec), and also co-founder of Ora Capital plc. David has been a founder and/or director of many UK technology companies including Oxford Nanopore, Proximagen, Synairgen, Ilika, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy). He has also acted as seed investor and/or advisor to Wolfson Microelectronics, Nanoco, Tissue Regenix and Arc International (now part of Synopsys). He is also Chairman of Retroscreen Virology Limited, Europe's leading specialist virology contract research organisation.
Research Interest
science, technology
